B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 198.4 DKK 3.09% Market Closed
Market Cap: 15.6B DKK
Have any thoughts about
Bavarian Nordic A/S?
Write Note

Bavarian Nordic A/S
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bavarian Nordic A/S
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
B
Bavarian Nordic A/S
CSE:BAVA
Operating Expenses
-kr2.7B
CAGR 3-Years
-41%
CAGR 5-Years
-36%
CAGR 10-Years
-16%
Genmab A/S
CSE:GMAB
Operating Expenses
-kr12.4B
CAGR 3-Years
-43%
CAGR 5-Years
-42%
CAGR 10-Years
-35%
Zealand Pharma A/S
CSE:ZEAL
Operating Expenses
-kr1.2B
CAGR 3-Years
0%
CAGR 5-Years
-15%
CAGR 10-Years
-19%
Ascendis Pharma A/S
NASDAQ:ASND
Operating Expenses
-€625.2m
CAGR 3-Years
-14%
CAGR 5-Years
-25%
CAGR 10-Years
-42%
F
Fluoguide AS
STO:FLUO
Operating Expenses
-kr43.9m
CAGR 3-Years
-26%
CAGR 5-Years
-285%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Operating Expenses
-kr82m
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-10%
No Stocks Found

Bavarian Nordic A/S
Glance View

Market Cap
15.5B DKK
Industry
Biotechnology

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The firm is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

BAVA Intrinsic Value
168.42 DKK
Overvaluation 15%
Intrinsic Value
Price
B

See Also

What is Bavarian Nordic A/S's Operating Expenses?
Operating Expenses
-2.7B DKK

Based on the financial report for Jun 30, 2024, Bavarian Nordic A/S's Operating Expenses amounts to -2.7B DKK.

What is Bavarian Nordic A/S's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-16%

Over the last year, the Operating Expenses growth was -16%. The average annual Operating Expenses growth rates for Bavarian Nordic A/S have been -41% over the past three years , -36% over the past five years , and -16% over the past ten years .

Back to Top